Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.

Blood
Philippe MoreauThierry Facon

Abstract

This phase 1/2 dose-escalation study investigated the combination of carfilzomib with melphalan and prednisone (CMP) in patients aged >65 years with newly diagnosed multiple myeloma (MM). Melphalan and prednisone were administered orally on days 1 to 4; carfilzomib was IV administered on days 1, 2, 8, 9, 22, 23, 29, and 30 of a 42-day cycle. Patients received up to 9 cycles of CMP. In the phase 1 dose-escalation portion, the primary objectives were to determine the incidence of dose-limiting toxicities during the first cycle of CMP treatment to define the maximal tolerated dose (MTD) of carfilzomib. In the phase 2 portion, the primary objective was to evaluate the overall response rate (ORR) of CMP. In the phase 1 portion of the study, 24 patients received CMP at carfilzomib dosing levels of 20 mg/m(2), 27 mg/m(2), 36 mg/m(2), and 45 mg/m(2). The MTD was established as 36 mg/m(2). In the phase 2 portion of the study, 44 patients were enrolled at the MTD. Among 50 efficacy-evaluable patients treated at the MTD, the ORR was 90%. The projected 3-year overall survival rate was 80%. The combination of CMP was observed to be effective in elderly patients with newly diagnosed MM. This trial was registered at www.clinicaltrials.gov as ...Continue Reading

References

Mar 17, 2001·Statistics in Medicine·R P A'Hern
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Oct 12, 2010·The Lancet Oncology·Michel DelforgePieter Sonneveld
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
Feb 9, 2013·Blood·K Martin Kortuem, A Keith Stewart
Jan 15, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboRobert Z Orlowski
Sep 4, 2014·The New England Journal of Medicine·Lotfi BenboubkerUNKNOWN FIRST Trial Team
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators

❮ Previous
Next ❯

Citations

Sep 4, 2015·Expert Review of Hematology·María J Cejalvo, Javier de la Rubia
Aug 16, 2015·Current Hematologic Malignancy Reports·Karie D Runcie, Tomer M Mark
Feb 20, 2016·European Journal of Haematology·Eli MuchtarHila Magen
May 11, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Tulio E RodriguezDavid H Vesole
Jul 30, 2016·Blood Cancer Journal·Y ChenS K Gopalakrishnan
Feb 17, 2017·Journal of Internal Medicine·O Landgren, K Iskander
May 16, 2017·Expert Review of Hematology·Sonja Genadieva StavricAlessandra Larocca
Apr 1, 2018·European Journal of Haematology·Kwee YongRoman Hajek
Aug 30, 2017·Leukemia & Lymphoma·Evan DiamondHeather Landau
Nov 15, 2017·Expert Opinion on Pharmacotherapy·Dimitrios C ZiogasMeletios A Dimopoulos
Jul 31, 2018·Future Oncology·Susanne Strifler, Stefan Knop
Feb 22, 2018·Leukemia & Lymphoma·Chintan ShahJan S Moreb
Dec 22, 2017·Expert Opinion on Pharmacotherapy·Massimo OffidaniSilvia Gentili
Jul 2, 2016·Journal of Hematology & Oncology·Leonard Naymagon, Maher Abdul-Hay
Jan 25, 2017·Nature Reviews. Clinical Oncology·Elisabet E Manasanch, Robert Z Orlowski
May 6, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xavier LeleuThierry Facon
Nov 8, 2020·Journal of Clinical Medicine·Hélène GardeneyStéphanie Guidez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.